Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in Switzerland.

ABSTRACT: Rising numbers of campylobacteriosis case notifications in Switzerland resulted in an increased attention to acute gastroenteritis (AG) in general. Patients with a laboratory-confirmed Campylobacter infection perceive their disease as severe and around 15% of these patients are hospitalized. This study aimed at estimating healthcare costs due to AG and campylobacteriosis in Switzerland. We used official health statistics, data from different studies and expert opinion for estimating individual treatment costs for patients with different illness severity and for extrapolating overall costs due to AG and campylobacteriosis. We estimated that total Swiss healthcare costs resulting from these diseases amount to €29-45 million annually. Data suggest that patients with AG consulting a physician

SUBMITTER: Schmutz C 

PROVIDER: S-EPMC5426335 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature